Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after mo...
Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events
About this item
Full title
Author / Creator
Kawahira, Machiko , Kanmura, Shuji , Mizuno, Keiko , Machida, Kentaro , Ohtsuka, Takao , Sato, Masami , Enokida, Hideki , Yamashita, Masaru , Kanekura, Takuro , Arima, Shiho , Nakamura, Norifumi , Sugiura, Tsuyoshi , Yoshimoto, Koji , Kobayashi, Hiroaki , Ishitsuka, Kenji , Suzuki, Shinsuke , Ueno, Shinichi and Ido, Akio
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
Immune checkpoint inhibitors (ICIs) are used to treat several cancers, but they sometimes induce immune-related adverse events (irAEs). Patients with irAEs often have improved antitumor responses, but discontinuation of ICIs after irAEs is considered necessary. Resuming the use of ICIs after irAEs is preferable, but few studies have investigated th...
Alternative Titles
Full title
Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_2656781434
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2656781434
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0267572
